Vaccinex
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1895 Mount Hope Ave, Rochester, New York...Phone Number
(585) 271-2700Website
www.vaccinex.comRevenue
<$5 MillionStock Symbol
VCNXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Vaccinex
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.Explore more
Vaccinex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vaccinex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Vaccinex has new funding data
Product Launch: Get notified when Vaccinex launches new products
Check if Vaccinex has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Vaccinex recently announced quarterly report
Check out if Vaccinex is spiking on competitors!
Click to see if Vaccinex had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Vaccinex, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Vaccinex
Recommended Actions
Reach out to Masked Content who joined Vaccinex as Masked Content
Find 2 more new buyers
Compare Similar Companies to Vaccinex
Compare insights from companies similar to Vaccinex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vaccinex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vaccinex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vaccinex.
Vaccinex financials insights
Gather financial insights about Vaccinex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$6M
2020
Share Placement
$16.5M
Debt
$1M
Vaccinex Tech Stack
A closer look at the technologies used by Vaccinex
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Earnings
Earnings
Earnings
Partnership
Earnings
Vaccinex News & Media
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatmeVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasd
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Vaccinex
Sign Up For FreeTo access detailed company insights
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.... Read More
